This is a summary. To read the whole story subscribe to BostonGlobe.com
Laboratory science supplier Thermo Fisher Scientific Inc. said Monday that it has completed the sale of its cell culture, gene modulation, and magnetic beads businesses to GE Healthcare, a unit of General Electric Co., for $1.065 billion. The deal was first announced in January, and it enabled Waltham-based Thermo Fisher Scientific to complete a giant buyout of Life Technologies Corp. The divestitures were required to fulfill an agreement struck between Thermo Fisher and European regulators in November that will allow the company to move forward with its Life Technologies acquisition, gaining an entree into the personalized medicine market. Thermo Fisher agreed last April to pay $13.6 billion for Life Technologies, a diagnostics equipment maker. The acquisition of Life Technologies was completed Feb. 3.